title: Nasal-type NK/T cell lymphoma: clinical features and treatment outcome.
abstract: Nasal-type NK/T cell lymphoma is an increasingly recognised disease entity of aggressive clinical behaviour. The objective of this study was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma. From January 1991 to December 2003, 26 patients diagnosed as nasal-type NK/T cell lymphoma were included in the analysis. One half of patients presented with poor performance status (ECOG > or =2); 46% of patients were categorised as high intermediate or high-risk group according to IPI; and 46% of patients were diagnosed at advanced stage. The median survival for 26 patients with nasal-type NK/T cell lymphoma was 7.4 months (95% CI, 0.1, 16.9). The treatment outcome of primary anthracycline-based chemotherapy was poor: 60% CR rate in localised disease and 0% CR rate in advanced disease. After a median follow-up of 24.4 months (range 3.1-99.0) in patients with localised disease who had achieved a CR (range 29.6-165.7), three patients (50.0%) developed disease recurrence at 6.1, 21.8, and 52.1 months, respectively, and all patients presented with locoregional failure. The predictive factors for poor survival were of age greater than 60, advanced stage and poor performance in multivariate analysis. In conclusion, Nasal-type NK/T cell lymphomas showed a poor response to the conventional anthracycline-based chemotherapy, and thus an investigation for an innovative therapy is urgently needed to improve survival in these patients.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong Kangnam-ku, Seoul 135-710, Korea.
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: W S
authors.initials: WS
authors.lastname: Kim
authors.forename: Y H
authors.initials: YH
authors.lastname: Park
authors.forename: S H
authors.initials: SH
authors.lastname: Park
authors.forename: K W
authors.initials: KW
authors.lastname: Park
authors.forename: J H
authors.initials: JH
authors.lastname: Kang
authors.forename: S S
authors.initials: SS
authors.lastname: Lee
authors.forename: S I
authors.initials: SI
authors.lastname: Lee
authors.forename: S-H
authors.initials: SH
authors.lastname: Lee
authors.forename: K
authors.initials: K
authors.lastname: Kim
authors.forename: C W
authors.initials: CW
authors.lastname: Jung
authors.forename: Y C
authors.initials: YC
authors.lastname: Ahn
authors.forename: Y H
authors.initials: YH
authors.lastname: Ko
authors.forename: K
authors.initials: K
authors.lastname: Park
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006304:Health Status; D006801:Humans; D007694:Killer Cells, Natural; D016399:Lymphoma, T-Cell; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009296:Nasal Cavity / Q000473:pathology*; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000188:drug therapy / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents